In this exclusive session chaired by María-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, Marta Chesi, PhD, Mayo Clinic, Phoenix, AZ, Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, and José Ángel Martínez Climent, MD, PhD, University of Navarra, Pamplona, Spain, comment on future strategies and novel targets in multiple myeloma. The experts comment on recapitulating genomic heterogeneity in mice and compare genetic lesions and myelomagenesis in mice and humans. They then move on to using the microenvironment to predict measurable residual disease (MRD) outcomes prior to therapy, and finish by discussing risk models to identify smoldering myeloma. This session was filmed at the 16th International Workshop on Multiple Myeloma (iwMyeloma) held in Madrid, Spain.